• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Media-journal collaboration often leads to misinformation

Report: Media-journal collaboration often leads to misinformation

December 15, 2016
CenterWatch Staff

When flawed clinical research is reported in the media with hype and sensationalism, it has the potential to have a devastating effect on patients, physicians, the scientific community and eventually society as a whole.

In a review article in the journal EMBO Reports, the authors question how controversial and weak studies are publicized by the media and often coupled with a narrative that is either false or with little scientific basis. The blame for misleading the public, they believe, should be shouldered equally by journalists, scientists, journal editors and research institutions.

As an example, the authors describe the changes in medical attitudes and practices regarding the use of hormone replacement therapy (HRT) in peri- and post-menopausal women following intense coverage of the Women's Health Initiative study. In 2002, the media reported that this large study had been prematurely halted after it showed greater risks of stroke, death and invasive breast cancer for women who took estrogen and progesterone compared with those who received placebo. Physicians called for immediate curtailment of HRT use in women and prescriptions fell by more than 80% and remained at that level for years. Today, healthcare experts still routinely reference this study as demonstrating the dangers of HRT despite the fact that a 2013 follow-up study reported no significant difference between HRT and placebo for mortality or a long list of other adverse events.

"We believe that the collaboration between media and scientific journals in communicating advances in science and medicine to the public may result in misinformation and distortion. Unfortunately, this collaboration often exaggerates and allows bad science to be disseminated and shared. Media is often drawn to these controversial studies and they promote them with a narrative that is difficult to change even if it is wrong," explained lead author Abdulmaged M. Traish, Ph.D., professor of biochemistry and urology at Boston University School of Medicine.

Traish and his colleagues believe a number of strategies could help prevent medical professionals and the general public from accepting distorted study results and their coverage in the media, including recognizing the collaboration between medical journals; being wary of pronouncements from individuals who are unlikely to have clinical experience with a drug or treatment and recognizing the limitations of any one study since as many as 70% of the most highly cited studies eventually prove to be unreproducible.

Traish believes this critical analysis of how the media and medical journals promote questionable studies is of critical importance to the public, academics, policy makers and research institutions. "This is an issue that needs to be discussed, debated and taught to our medical students to be prepared to enter the real world of medicine and its complexities."

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing